Not exact matches
Clinical
symptoms developed, but guanabenz administered a week
after immunization significantly delayed the onset of these
symptoms and reduced peak severity.
The primary outcome was safety, measured as 1) occurrence of solicited
symptoms during a 7 - day follow - up period
after immunization (day of
immunization and days 1, 2, 3 and 7
after immunization); 2) occurrence of unsolicited
symptoms during a 30 - day follow - up period
after each
immunization (day of
immunization and 29 subsequent days); and 3) occurrence of serious adverse events (SAE) during the study period.
Unsolicited signs and
symptoms were recorded during the 30 days
after each
immunization, whereas SAEs were monitored throughout the 12 - month study period.
The observation of adverse
symptoms not typically seen
after a vaccine is considered a reaction to the
immunization.